171 related articles for article (PubMed ID: 16652387)
1. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
Sutton MT; Yingling M; Vyas A; Atiemo H; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2006 Aug; 66(11):1194-202. PubMed ID: 16652387
[TBL] [Abstract][Full Text] [Related]
2. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
[TBL] [Abstract][Full Text] [Related]
3. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.
Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S
Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489
[TBL] [Abstract][Full Text] [Related]
4. Effects of finasteride on vascular endothelial growth factor.
Häggström S; Tørring N; Møller K; Jensen E; Lund L; Nielsen JE; Bergh A; Damber JE
Scand J Urol Nephrol; 2002; 36(3):182-7. PubMed ID: 12201932
[TBL] [Abstract][Full Text] [Related]
5. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
6. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
7. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
9. Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study.
Kaya C; Ozyurek M; Turkeri LN
Int J Urol; 2005 Feb; 12(2):194-8. PubMed ID: 15733115
[TBL] [Abstract][Full Text] [Related]
10. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
[TBL] [Abstract][Full Text] [Related]
11. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks.
Donohue JF; Hayne D; Karnik U; Thomas DR; Foster MC
BJU Int; 2005 Dec; 96(9):1319-22. PubMed ID: 16287453
[TBL] [Abstract][Full Text] [Related]
12. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
[TBL] [Abstract][Full Text] [Related]
13. Early diagnosis of prostate cancer in finasteride treated BPH patients.
Tarle M; Kraus O; Trnski D; Reljic A; Ruzic B; Katusic J; Spajic B; Kusic Z
Anticancer Res; 2003; 23(1B):693-6. PubMed ID: 12680169
[TBL] [Abstract][Full Text] [Related]
14. In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia.
Park HS; Cheon J; Cho HY; Ko YH; Bae JH; Moon DG; Kim JJ
Gene Ther; 2003 Jul; 10(13):1129-34. PubMed ID: 12808443
[TBL] [Abstract][Full Text] [Related]
15. Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia.
Bozec A; Ruffion A; Decaussin M; Andre J; Devonec M; Benahmed M; Mauduit C
J Clin Endocrinol Metab; 2005 Jan; 90(1):17-25. PubMed ID: 15507514
[TBL] [Abstract][Full Text] [Related]
16. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia.
Lekas AG; Lazaris AC; Chrisofos M; Papatsoris AG; Lappas D; Patsouris E; Deliveliotis C
Urology; 2006 Aug; 68(2):436-41. PubMed ID: 16904480
[TBL] [Abstract][Full Text] [Related]
17. Effect of finasteride (Proscar) on the proliferation of cultured epithelial and stromal cells from normal and hyperplastic human prostates.
Lobaccaro JM; Boudon C; Lechevallier E; Mottet N; Rebillard X; Lumbroso S; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1996 Jun; 42(4):511-8. PubMed ID: 8828906
[TBL] [Abstract][Full Text] [Related]
18. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
[TBL] [Abstract][Full Text] [Related]
19. Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line.
Golbano JM; Lóppez-Aparicio P; Recio MN; Pérez-Albarsanz MA
Int J Oncol; 2008 Apr; 32(4):919-24. PubMed ID: 18360719
[TBL] [Abstract][Full Text] [Related]
20. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
